Slingshot members are tracking this event:
ZIOPHARM (ZIOP) to complete Phase 1/2 trial of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer by August 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Sep 18, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Single Arm Study, Open-label, Phase 1/2 Trial, Ad-rts-hil-12, Veledimex, Breast Cancer, Metastatic Breast Cancer